查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1945489

2026年全球肝癌診斷市場報告

Liver Cancer Diagnostics Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，肝癌診斷市場成長顯著，預計將從2025年的103.2億美元成長到2026年的110.7億美元，複合年成長率為7.3%。過去幾年的成長可歸因於慢性肝病盛行率的上升、肝細胞癌發生率的增加、醫院診斷基礎設施的擴建、早期癌症篩檢意識提升以及影像診斷和病理技術的進步。

預計未來幾年肝癌診斷市場規模將維持強勁成長，2030年將達到147.5億美元，複合年成長率（CAGR）為7.4%。預測期內的成長可歸因於精準腫瘤診斷技術的日益普及、對非侵入性診斷方法需求的不斷成長、分子檢測能力的提升、腫瘤研究投入的增加以及人工智慧輔助診斷平台的廣泛應用。預測期內的關鍵趨勢包括：先進分子診斷檢測技術的日益普及、基於影像的早期檢測工具的廣泛應用、基於生物標記的篩檢方法的日益整合、個性化癌症診斷的擴展以及對早期癌症檢測的日益重視。

預計肝癌發生率的上升將推動肝癌診斷市場的成長。肝癌的特徵是肝細胞不受控制地增殖，並會帶來嚴重的健康風險。肝癌診斷測試在確定原發性肝癌確診後癌細胞在肝臟內或周圍的擴散程度方面發揮著至關重要的作用。根據美國癌症協會 (ACS) 的報告，女性肝癌和肝內膽管癌的新病例數正在上升，預計到 2023 年，美國將達到 13,230 例。預計 2023 年美國新增肝癌病例總數將達 41,210 例，預計死亡人數將達 29,380 人。這凸顯了在肝癌發生率不斷上升的情況下，肝癌診斷的迫切性。

肝癌診斷市場的主要企業正在開發先進的基於生物標記的檢測方法和演算法，以提高診斷準確性並促進早期發現。基於生物標記的檢測方法和演算法是利用特定生物標記來識別疾病的診斷工具，能夠提供更精準、更有效率的診斷能力。例如，2023年11月，美國生物技術公司羅氏診斷推出了Elexis PIVKA-II檢測和Elexis GAAD演算法。 Elexis PIVKA-II檢測能夠辨識PIVKA-II水平升高，PIVKA-II是一種與肝細胞癌（HCC）相關的生物標記物，從而提高高風險患者肝癌的早期檢出率。同時，Elexis GAAD演算法結合了包括PIVKA-II和AFP在內的多種診斷標記物，旨在提高診斷準確性並簡化肝癌檢測的決策過程。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球肝癌診斷市場：吸引力評分及分析
  • 成長潛力分析、競爭評估、策略契合度評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 主要原料、資源和供應商清單
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章 全球市場趨勢與策略

  • 關鍵技術和未來趨勢
    • 生物技術、基因組學和精準醫學
    • 人工智慧（AI）和自主人工智慧
    • 數位化、雲端運算、巨量資料、網路安全
    • 工業4.0和智慧製造
    • 物聯網、智慧基礎設施和互聯生態系統
  • 主要趨勢
    • 先進分子診斷測試的普及率不斷提高
    • 更多地使用基於成像的早期檢測工具
    • 生物標記篩檢方法整合的進展
    • 擴大個人化癌症診斷
    • 人們越來越重視癌症早期檢測

第5章 終端用戶產業市場分析

  • 醫院
  • 診斷檢查室
  • 學術研究機構
  • 製藥公司
  • CRO（受託研究機構）

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及新冠疫情對市場的影響

第7章 全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球肝癌診斷市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 全球肝癌診斷市場規模、對比及成長率分析
  • 全球肝癌診斷市場表現：規模與成長，2020-2025年
  • 全球肝癌診斷市場預測：規模與成長，2025-2030年，2035年預測

第8章 全球潛在市場規模（TAM）

第9章 市場細分

  • 按類型
  • 肝細胞癌、膽管癌、肝母細胞瘤
  • 透過篩檢
  • 檢查室檢查、影像學檢查、切片檢查和其他篩檢
  • 透過技術
  • 螢光原位雜合反應（FISH）、免疫組織化學（IHC）及其他技術
  • 按最終用途
  • 醫院及診斷檢查室、學術研究機構
  • 按類型細分：肝細胞癌
  • 早期肝細胞癌，晚期肝細胞癌
  • 按類型細分：膽管癌
  • 肝內膽管癌，肝外膽管癌
  • 依類型細分：肝母細胞瘤
  • 純型肝母細胞瘤，混合型肝母細胞瘤

第10章 區域與國家分析

  • 全球肝癌診斷市場：依地區、績效及預測分類，2020-2025年、2025-2030年預測、2035年預測
  • 全球肝癌診斷市場：依國家、績效及預測分類，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章 印度市場

第14章 日本市場

第15章：澳洲市場

第16章 印尼市場

第17章 韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章：西歐市場

第21章英國市場

第22章 德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章 東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章 南美洲市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 肝癌診斷市場：競爭格局及市場佔有率（2024年）
  • 肝癌診斷市場：公司估值矩陣
  • 肝癌診斷市場：公司概況
    • Abbott Laboratories
    • F Hoffmann La Roche Ltd
    • Qiagen NV
    • Thermo Fisher Scientific Inc
    • Siemens Healthineers

第37章：其他領先和創新企業

  • Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH

第38章 全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年肝癌診斷市場：提供新機會的國家
  • 2030年肝癌診斷市場：蘊藏新機會的細分市場
  • 2030年肝癌診斷市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第41章附錄

簡介目錄
Product Code: ME4MLCDA01_G26Q1

Liver cancer diagnostics encompass a range of techniques utilized for the identification and assessment of liver cancer, a malignancy originating in the liver. These methods play a crucial role in the early detection and diagnosis of liver cancer, utilizing both imaging and molecular testing.

Hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other related forms constitute the primary types of cancer addressed in liver cancer diagnostics. Hepatocellular carcinoma (HCC) specifically pertains to the predominant liver cancer affecting individuals with cirrhosis and preexisting chronic liver disease. The screening process involves various approaches such as laboratory testing, imaging, endoscopy, biopsy, and others. Diverse technologies, including fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), among others, are employed across different end uses, including hospitals and diagnostic laboratories, academic and research institutes, and pharmaceutical and CRO laboratories.

Tariffs are impacting the liver cancer diagnostics market by increasing costs of imported imaging systems, laboratory analyzers, reagents, molecular testing kits, and diagnostic consumables used across hospitals and diagnostic laboratories. North America and Europe are most affected due to reliance on advanced imported diagnostic equipment, while Asia-Pacific faces cost pressures on reagents and imaging device imports. These tariffs are raising diagnostic procedure costs and slowing equipment upgrades. However, they are also encouraging domestic manufacturing of diagnostic kits, regional reagent production, and localized development of imaging and molecular diagnostic technologies.

The liver cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides liver cancer diagnostics market statistics, including liver cancer diagnostics industry global market size, regional shares, competitors with a liver cancer diagnostics market share, detailed liver cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer diagnostics industry. This liver cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver cancer diagnostics market size has grown strongly in recent years. It will grow from $10.32 billion in 2025 to $11.07 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of chronic liver diseases, rising incidence of hepatocellular carcinoma, expansion of hospital diagnostic infrastructure, growing awareness of early cancer screening, advancements in imaging and pathology techniques.

The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $14.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising demand for non-invasive diagnostic methods, expansion of molecular testing capabilities, growing investments in oncology research, increasing use of ai-assisted diagnostic platforms. Major trends in the forecast period include increasing adoption of advanced molecular diagnostic tests, rising use of imaging-based early detection tools, growing integration of biomarker-based screening methods, expansion of personalized oncology diagnostics, enhanced focus on early-stage cancer detection.

The anticipated rise in the prevalence of liver cancer is set to drive the growth of the liver cancer diagnostics market. Liver cancer, characterized by the uncontrolled growth of liver cells, poses a severe health risk. Diagnostic tests for liver cancer play a crucial role in determining the extent of cancer cell spread within or around the liver following the diagnosis of primary liver carcinoma. A report from the American Cancer Society revealed an increase in new cases of liver and intrahepatic bile duct cancer among females, reaching 13,230 in 2023 in the United States. The total estimated new cases of liver cancer for 2023 in the US are 41,210, with an expected 29,380 fatalities. This underscores the pressing need for liver cancer diagnostics due to the escalating prevalence of the disease.

Key companies in the liver cancer diagnostics market are creating advanced biomarker-based assays and algorithms to enhance diagnostic accuracy and facilitate early detection. Biomarker-based assays and algorithms are diagnostic tools that employ specific biological markers to identify diseases, offering more precise and efficient diagnostic capabilities. For example, in November 2023, Roche Diagnostics, a U.S.-based biotech corporation, introduced the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm. The Elecsys PIVKA-II assay identifies elevated levels of the PIVKA-II biomarker, which is linked to hepatocellular carcinoma (HCC), thereby improving early liver cancer detection in high-risk patients. Meanwhile, the Elecsys GAAD algorithm combines various diagnostic markers, including PIVKA-II and AFP, to enhance diagnostic accuracy and streamline decision-making in liver cancer detection.

In December 2024, Metropolis Healthcare Limited, an India-based healthcare diagnostics company, acquired Core Diagnostics for USD 0.0278 billion. Through this acquisition, Metropolis aims to substantially strengthen its advanced cancer testing capabilities and broaden its footprint across northern and eastern India, reinforcing its position in the specialized diagnostics segment. Core Diagnostics Private Limited is an India-based specialty diagnostics company that offers advanced testing solutions focused on liver cancer diagnostics.

Major companies operating in the liver cancer diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, Qiagen NV, Thermo Fisher Scientific Inc, Siemens Healthineers, Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon AS, BioGenex Laboratories Inc, OncoCyte Corporation, Guardant Health Inc, Exact Sciences Corporation, Grail Inc, Freenome Holdings Inc, Natera Inc, Personal Genome Diagnostics Inc, Thrive Earlier Detection Corp

North America was the largest region in the liver cancer diagnostics market in 2025. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The liver cancer diagnostics market includes revenues earned by entities by liver transplants, CT scans, and liver function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer diagnostics market also includes sales of In Vitro and Imaging Tools, AI tools, and ML tools which are used in providing liver cancer diagnostic services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liver Cancer Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses liver cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The liver cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatoblastoma
  • 2) By Screening: Laboratory Testing; Imaging; Biopsy; Other Screenings
  • 3) By Technology: Fluorescent In Situ Hybridization (FISH); Immunohistochemical (IHC); Other Technologies
  • 4) By End Use: Hospitals And Diagnostic Laboratories; Academic And Research Institutes
  • Subsegments:
  • 1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma; Advanced-Stage Hepatocellular Carcinoma
  • 2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma
  • 3) By Hepatoblastoma: Pure Hepatoblastoma; Mixed Hepatoblastoma
  • Companies Mentioned: Abbott Laboratories; F Hoffmann La Roche Ltd; Qiagen NV; Thermo Fisher Scientific Inc; Siemens Healthineers; Illumina Inc; Koninklijke Philips NV; Epigenomics AG; Digna Biotech SL; Biocept Inc; Danaher Corporation; Foundation Medicine Inc; Agilent Technologies Inc; Genemed Biotechnologies Inc; Merck KGaA; Fujifilm Medical Systems USA Inc; GE Healthcare; Advanced Cell Diagnostics Inc; Oxford Gene Technology; Leica Biosystems Nussloch GmbH; Exiqon AS; BioGenex Laboratories Inc; OncoCyte Corporation; Guardant Health Inc; Exact Sciences Corporation; Grail Inc; Freenome Holdings Inc; Natera Inc; Personal Genome Diagnostics Inc; Thrive Earlier Detection Corp
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Liver Cancer Diagnostics Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Liver Cancer Diagnostics Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Liver Cancer Diagnostics Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Liver Cancer Diagnostics Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Advanced Molecular Diagnostic Tests
    • 4.2.2 Rising Use Of Imaging-Based Early Detection Tools
    • 4.2.3 Growing Integration Of Biomarker-Based Screening Methods
    • 4.2.4 Expansion Of Personalized Oncology Diagnostics
    • 4.2.5 Enhanced Focus On Early-Stage Cancer Detection

5. Liver Cancer Diagnostics Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Diagnostic Laboratories
  • 5.3 Academic And Research Institutes
  • 5.4 Pharmaceutical Companies
  • 5.5 Contract Research Organizations

6. Liver Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Liver Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Liver Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Liver Cancer Diagnostics Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Liver Cancer Diagnostics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Liver Cancer Diagnostics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Liver Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Liver Cancer Diagnostics Market Segmentation

  • 9.1. Global Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma
  • 9.2. Global Liver Cancer Diagnostics Market, Segmentation By Screening, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Laboratory Testing, Imaging, Biopsy, Other Screenings
  • 9.3. Global Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Fluorescent In Situ Hybridization (FISH), Immunohistochemical (IHC), Other Technologies
  • 9.4. Global Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Diagnostic Laboratories, Academic And Research Institutes
  • 9.5. Global Liver Cancer Diagnostics Market, Sub-Segmentation Of Hepatocellular Carcinoma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma
  • 9.6. Global Liver Cancer Diagnostics Market, Sub-Segmentation Of Cholangiocarcinoma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
  • 9.7. Global Liver Cancer Diagnostics Market, Sub-Segmentation Of Hepatoblastoma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Pure Hepatoblastoma, Mixed Hepatoblastoma

10. Liver Cancer Diagnostics Market Regional And Country Analysis

  • 10.1. Global Liver Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Liver Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Liver Cancer Diagnostics Market

  • 11.1. Asia-Pacific Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Liver Cancer Diagnostics Market

  • 12.1. China Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Liver Cancer Diagnostics Market

  • 13.1. India Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Liver Cancer Diagnostics Market

  • 14.1. Japan Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Liver Cancer Diagnostics Market

  • 15.1. Australia Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Liver Cancer Diagnostics Market

  • 16.1. Indonesia Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Liver Cancer Diagnostics Market

  • 17.1. South Korea Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Liver Cancer Diagnostics Market

  • 18.1. Taiwan Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Liver Cancer Diagnostics Market

  • 19.1. South East Asia Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Liver Cancer Diagnostics Market

  • 20.1. Western Europe Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Liver Cancer Diagnostics Market

  • 21.1. UK Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Liver Cancer Diagnostics Market

  • 22.1. Germany Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Liver Cancer Diagnostics Market

  • 23.1. France Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Liver Cancer Diagnostics Market

  • 24.1. Italy Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Liver Cancer Diagnostics Market

  • 25.1. Spain Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Liver Cancer Diagnostics Market

  • 26.1. Eastern Europe Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Liver Cancer Diagnostics Market

  • 27.1. Russia Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Liver Cancer Diagnostics Market

  • 28.1. North America Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Liver Cancer Diagnostics Market

  • 29.1. USA Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Liver Cancer Diagnostics Market

  • 30.1. Canada Liver Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Liver Cancer Diagnostics Market

  • 31.1. South America Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Liver Cancer Diagnostics Market

  • 32.1. Brazil Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Liver Cancer Diagnostics Market

  • 33.1. Middle East Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Liver Cancer Diagnostics Market

  • 34.1. Africa Liver Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Liver Cancer Diagnostics Market, Segmentation By Type, Segmentation By Screening, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Liver Cancer Diagnostics Market Regulatory and Investment Landscape

36. Liver Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 36.1. Liver Cancer Diagnostics Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Liver Cancer Diagnostics Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Liver Cancer Diagnostics Market Company Profiles
    • 36.3.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. F Hoffmann La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Qiagen NV Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

37. Liver Cancer Diagnostics Market Other Major And Innovative Companies

  • Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH

38. Global Liver Cancer Diagnostics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Liver Cancer Diagnostics Market

40. Liver Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 40.1 Liver Cancer Diagnostics Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Liver Cancer Diagnostics Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Liver Cancer Diagnostics Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer